Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics

Madison Stoddard, Lin Yuan, Arijit Chakravarty
doi: https://doi.org/10.1101/2021.03.11.21253375
Madison Stoddard
1Fractal Therapeutics Inc, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: madison.stoddard@fractaltx.com
Lin Yuan
1Fractal Therapeutics Inc, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arijit Chakravarty
1Fractal Therapeutics Inc, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The ongoing COVID-19 pandemic has created an urgent need for antiviral treatments that can be deployed rapidly. Drug repurposing represents a promising means of achieving this objective, but repurposing efforts are often unsuccessful. A common hurdle to effective drug repurposing is a failure to achieve a sufficient therapeutic window in the new indication. A clear example is the use of ivermectin in COVID-19, where the approved dose (administered orally) fails to achieve therapeutic concentrations in the lungs. Our proposed solution to the problem of ineffective drug repurposing for COVID-19 antivirals is two-fold: to broaden the therapeutic window by reformulating therapeutics for the pulmonary route, and to select drug repurposing candidates based on their model-predicted therapeutic index for inhalation. In this article, we propose a two-stage model-driven screening and validation process for selecting inhaled antiviral drug repurposing candidates. While we have applied this approach in the specific context of COVID-19, this in vitro-in vivo translational methodology is also broadly applicable to repurposing drugs for diseases of the lower respiratory tract.

Competing Interest Statement

MS, LY and AC are shareholders and employees of Fractal Therapeutics Inc. This work was funded by Fractal Therapeutics. Fractal Therapeutics does not benefit in any way from sharing the work here (strategy for identifying new antiviral combinations) with potential competitors.

Funding Statement

LY and MS's salaries were paid by Fractal Therapeutics.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The work describes a mathematical methodology based on publicly available data. All data used in the work was sourced from prior publications.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 12, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics
Madison Stoddard, Lin Yuan, Arijit Chakravarty
medRxiv 2021.03.11.21253375; doi: https://doi.org/10.1101/2021.03.11.21253375
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics
Madison Stoddard, Lin Yuan, Arijit Chakravarty
medRxiv 2021.03.11.21253375; doi: https://doi.org/10.1101/2021.03.11.21253375

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (519)
  • Anesthesia (124)
  • Cardiovascular Medicine (1406)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (580)
  • Epidemiology (10263)
  • Forensic Medicine (6)
  • Gastroenterology (525)
  • Genetic and Genomic Medicine (2611)
  • Geriatric Medicine (253)
  • Health Economics (495)
  • Health Informatics (1727)
  • Health Policy (788)
  • Health Systems and Quality Improvement (669)
  • Hematology (266)
  • HIV/AIDS (563)
  • Infectious Diseases (except HIV/AIDS) (12066)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (272)
  • Medical Ethics (83)
  • Nephrology (286)
  • Neurology (2448)
  • Nursing (143)
  • Nutrition (374)
  • Obstetrics and Gynecology (486)
  • Occupational and Environmental Health (565)
  • Oncology (1314)
  • Ophthalmology (397)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (341)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (328)
  • Primary Care Research (294)
  • Psychiatry and Clinical Psychology (2390)
  • Public and Global Health (4987)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (520)
  • Respiratory Medicine (680)
  • Rheumatology (307)
  • Sexual and Reproductive Health (253)
  • Sports Medicine (244)
  • Surgery (296)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)